Lasmiditan
- Generic Name
- Lasmiditan
- Brand Names
- Reyvow, Rayvow
- Drug Type
- Small Molecule
- Chemical Formula
- C19H18F3N3O2
- CAS Number
- 439239-90-4
- Unique Ingredient Identifier
- 760I9WM792
- Background
Lasmiditan is an oral medication used in the termination of migraine headaches that was first approved for use in the United States in October 2019. It was also approved by the European Commission on August 17, 2022.
...
- Indication
Lasmiditan is indicated for the acute treatment of migraine with or without aura in adults.
- Associated Conditions
- Migraine Headache, With or Without Aura
- Associated Therapies
- -
Ditan Acute tReatments: Effectiveness and Tolerability (DART)
- Conditions
- Interventions
- First Posted Date
- 2023-06-15
- Last Posted Date
- 2023-12-08
- Lead Sponsor
- University of Florence
- Target Recruit Count
- 100
- Registration Number
- NCT05903040
- Locations
- 🇮🇹
SOD Centro Cefalee e Farmacologia Clinica, AOU Careggi, Florence, Italy
🇮🇹IRCCS National Neurological Institute "C. Mondino" Foundation, Pavia, Italy
A Study to Compare Two Different Formulations of Lasmiditan in Healthy Participants
- First Posted Date
- 2021-05-11
- Last Posted Date
- 2023-03-23
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 47
- Registration Number
- NCT04881747
- Locations
- 🇺🇸
Covance Dallas, Dallas, Texas, United States
A Study of Lasmiditan in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2021-02-11
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 97
- Registration Number
- NCT04749914
- Locations
- 🇸🇬
Lilly Centre for Clinical Pharmacology, Singapore, Singapore
A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
- First Posted Date
- 2020-05-20
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1000
- Registration Number
- NCT04396574
- Locations
- 🇺🇸
Rochester Clinical Research, Inc., Rochester, New York, United States
🇧🇪Ziekenhuis Oost-Limburg, Campus St.-Jan, Genk, Limburg, Belgium
🇮🇹IRCCS Istituto Neurologico Carlo Besta, Milano, Lombardia, Italy
A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
- First Posted Date
- 2020-05-20
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1633
- Registration Number
- NCT04396236
- Locations
- 🇪🇸
Hospital Universitario La Paz-NEURO, Madrid, Spain
🇬🇧Queen's Medical Centre, Nottingham University Hospitals, Nottingham, Nottinghamshire, United Kingdom
🇬🇧Stepping Hill Hospital, Stockport, United Kingdom
A Study of Lasmiditan in Healthy Chinese Participants
- First Posted Date
- 2019-09-09
- Last Posted Date
- 2021-07-01
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 36
- Registration Number
- NCT04081324
- Locations
- 🇨🇳
HuaShan Hospital Affiliated To Fudan University, Shanghai, Shanghai, China
A Study of Lasmiditan (LY573144) in Children Aged 6 to 17 With Migraine
- First Posted Date
- 2019-06-17
- Last Posted Date
- 2020-09-01
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 18
- Registration Number
- NCT03988088
- Locations
- 🇯🇵
Clinical Research Hospital, Tokyo, Shinjuku-Ku, Tokyo, Japan
🇺🇸Newport Beach Clinical Research Associates, Inc., Newport Beach, California, United States
🇺🇸Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
A Study Lasmiditan (LY573144) in a Single Migraine Attack in Japanese Participants With Migraine
- First Posted Date
- 2019-05-24
- Last Posted Date
- 2021-06-11
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 846
- Registration Number
- NCT03962738
- Locations
- 🇯🇵
Osaka Saiseikai Nakatsu Hospital, Osaka, Japan
🇯🇵Tominaga Hospital, Osaka, Japan
🇯🇵Kohnan Hospital, Kobe, Hyogo, Japan
A Study of Lasmiditan (LY573144) Over Four Migraine Attacks
- First Posted Date
- 2018-09-14
- Last Posted Date
- 2022-07-29
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1633
- Registration Number
- NCT03670810
- Locations
- 🇦🇹
KH der Barmherzigen Schwestern Linz BetriebsGesmbH, Linz, Oberösterreich, Austria
🇩🇪Praxis für Neurologie und Psychiatrie, Essen, North Rhine-Westphalia, Germany
🇨🇳Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu, China
A Study of Lasmiditan in Healthy Japanese and Caucasian Participants
- First Posted Date
- 2018-07-09
- Last Posted Date
- 2019-11-29
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 27
- Registration Number
- NCT03579940
- Locations
- 🇺🇸
Covance, Dallas, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.